Funding in, findings out

For any dataset: the NCI award that paid to create it, and the awards that got a published finding out of it afterwards.

Pick a dataset

332 of 602 datasets have at least one award resolved. 31 have awards on both sides.

Datasets with awards on both sides - awards that paid to create it awards that funded work using it

TCGA-THYM 17 → 22 ORGANOID-PANCREATIC 13 → 49 CPTAC-3 10 → 36 WCDT-MCRPC 9 → 43 TCGA-STAD 18 → 10 BEATAML1.0-COHORT 7 → 33

prad_su2c_2015

Metastatic Prostate Cancer (SU2C/PCF Dream Team, Cell 2015)

21 awards paid to create it · 0 awards funded work that used it

Awards that paid to create this data (6 of 21)

Credited on the dataset's own marker paper

The dataset

Articles that used it

The accession appears in their methods section

Awards those articles were funded by

NCI money spent on data it did not pay to generate

The best connected are shown.

prad_su2c_2015Metastatic Prostate Cancer (SU2C/PCF Dream Team, Cell 2015)cBioPortal

No article can be traced to this dataset, so nothing it enabled is visible here.

None of the traced articles reports an NCI award.

Direct evidence: the award is on the paper, or the accession is in the articleWeaker: infrastructure support, or use declared but not shownHover any card to follow its chain

Why one side of this chain is empty

This dataset has no accession that articles quote, so no reuse can be traced and nothing it enabled is visible.

Awards that paid to create this data

Credited on the dataset's own marker paper.

Award	Project	Evidence
K08CA115927 K08FY2005–2009$684k	Integrated Functional Genomic Analyses of Melanoma Levi A. Garraway · DANA-FARBER CANCER INST	API
K08CA188615 K08FY2014–2017$708k	Resistance to Emerging Androgen Deprivation Therapies in Prostate Cancer Eliezer M Van Allen · DANA-FARBER CANCER INST	API
P01CA163227 P01FY2025$3.5M	Androgen Receptor Action in Castration Resistant Prostate Cancer Steven P. Balk, PETER S NELSON · BETH ISRAEL DEACONESS MEDICAL CENTER	API
P30CA006516 P30FY2025–2026$50.6M	Dana-Farber/Harvard Cancer Center Benjamin Levine Ebert, JEROME RITZ · DANA-FARBER CANCER INST	API
P30CA008748 P30FY2025–2026$48.4M	Antitumor Assessment Elisa de Stanchina, FRANCESCA M GANY · SLOAN-KETTERING INST CAN RESEARCH	API
P50CA069568 P50FY1995–2013$74.2M	SPORE in Prostate Cancer ARUL M CHINNAIYAN, KATHLEEN A COONEY · UNIVERSITY OF MICHIGAN AT ANN ARBOR	API
P50CA090381 P50FY2002–2017$56.3M	Tissue and Pathology Core Massimo Loda, PHILIP W KANTOFF · DANA-FARBER CANCER INST	API
P50CA092629 P50FY2025–2026$5.2M	SPORE in Prostate Cancer Yu Chen, MICHAEL J MORRIS · SLOAN-KETTERING INST CAN RESEARCH	API
P50CA097186 P50FY2025–2026$5.1M	Developmental Research Program RUTH D ETZIONI, Martin Edwin Gleave · FRED HUTCHINSON CANCER CENTER	API
P50CA186786 P50FY2023–2026$10.6M	Michigan Prostate SPORE 2025-2030 ARUL M CHINNAIYAN, Ganesh S Palapattu · UNIVERSITY OF MICHIGAN AT ANN ARBOR	API
R01CA085912 R01FY2000–2009$2.7M	Functional Analysis of the PTEN Tumor Suppressor Protein Levi A. Garraway, WILLIAM R SELLERS · DANA-FARBER CANCER INST	API
R01CA116337 R01FY2006–2016$5.3M	Molecular Signatures of Lethal and Indolent Prostate Cancer MARK A. RUBIN · WEILL MEDICAL COLL OF CORNELL UNIV	API
R01CA129435 R01FY2007–2009$1.5M	Fine mapping and characterization of the 8q24 prostate cancer risk locus MATTHEW L FREEDMAN · DANA-FARBER CANCER INST	API
R01CA131945 R01FY2008–2018$4.0M	Molecular Link Between Metabolic Syndrome and Prostate Cancer Massimo Loda · DANA-FARBER CANCER INST	API
R01CA136578 R01FY2009–2013$1.7M	Sex-Hormones and the TMPRSS2: ERG Fusion in Prostate Cancer Progression Lorelei Mucci · BRIGHAM AND WOMEN'S HOSPITAL	API
R01CA155169 R01FY2012–2022$3.8M	Understanding Resistance to Next Generation Antiandrogens CHARLES L. SAWYERS · SLOAN-KETTERING INST CAN RESEARCH	API
R01CA193837 R01FY2015–2025$4.7M	Role of ETS factors in specifying prostate luminal cell identity and androgen receptor dependence CHARLES L. SAWYERS · SLOAN-KETTERING INST CAN RESEARCH	API
R01CA193910 R01FY2015–2019$3.1M	Defining the epigenetic landscape in human prostate cancer MYLES A BROWN, MATTHEW L FREEDMAN · DANA-FARBER CANCER INST	API
R21CA128352 R21FY2008–2009$532k	A phase II study of IPI-504 in metastatic hormone refractory prostate cancer William K. Oh · DANA-FARBER CANCER INST	API
T32CA009437 T32FY1996–2001$2.4M	MOLECULAR TRAINING PROGRAM IN CANCER RESEARCH - COMPETIN LAWRENCE A LOEB · UNIVERSITY OF WASHINGTON	API
U01CA111275 U01FY2004–2015$6.8M	A Systems Biology Approach to the Development of Cancer Biomarkers ARUL M CHINNAIYAN, MARK A. RUBIN · UNIVERSITY OF MICHIGAN AT ANN ARBOR	API

Where the links come from

NIH RePORTER maps a PMID to the awards that reported it. On a dataset’s marker paper that gives the awards which created it; on an article that used the data, the awards which funded that use.

The two sides are not measured alike. Generation is complete: a dataset has one marker paper and every award on it is resolved. Reuse is a sample - the articles using a dataset can number in the thousands, and only the few dozen strongest are retrieved and looked up. Every award shown here funded reuse; there are more that are not shown.

How far it reaches

283 datasets have an award credited with creating them, 80 with using them, and 31 both.

What is missing

No citable accession means no traceable articles; no authoritative marker paper means no attributable generation award. Absence is a gap in the record. Methods.

Start from an award instead, and see every dataset it touches.